title: Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong.
abstract: Incorporating various new and conventional risk factors, the 2005 St Gallen risk categorization is a potentially useful prognostic tool for breast cancers. We conducted a retrospective study to evaluate its application in Hong Kong. Of the 902 included female breast cancers with median follow-up of 5.4 years, 7%, 63% and 30% patients were classified as low-, intermediate- and high-risk categories, respectively. Their corresponding 5-year distant disease-free survivals (DDFS) were 100%, 92% and 72%, respectively (p<0.00005). In the intermediate-risk category, node-positive patients had marginally inferior 5-year DDFS than node-negative patients (89% vs. 93%, p=0.0551). In the high-risk category, patients having HER2 overexpressed tumors and 1-3 positive nodes had significantly better DDFS than other patients with > or = 4 positive nodes (89% vs. 65%, p=0.0001). Overall, the 2005 St Gallen risk categorization had high prognostic value. However, the impact of HER2 overexpression might be affected by reproducibility of HER2 tests.
authors.affiliation: Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong SAR, People's Republic of China. tkokyau@gmail.com
authors.forename: T K
authors.initials: TK
authors.lastname: Yau
authors.forename: I S
authors.initials: IS
authors.lastname: Soong
authors.forename: K
authors.initials: K
authors.lastname: Chan
authors.forename: A
authors.initials: A
authors.lastname: Chang
authors.forename: H
authors.initials: H
authors.lastname: Sze
authors.forename: M W
authors.initials: MW
authors.lastname: Yeung
authors.forename: R
authors.initials: R
authors.lastname: Tung
authors.forename: S
authors.initials: S
authors.lastname: Lau
authors.forename: A
authors.initials: A
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D002277:Carcinoma / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D020869:Gene Expression Profiling; D018734:Genes, erbB-2; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy / Q000706:statistics & numerical data; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome